Update shared on01 Aug 2025
Fair value Decreased 22%The notable downward revision in NeoGenomics’ analyst price target reflects reduced revenue growth forecasts and a lower forward P/E, resulting in a new fair value estimate of $8.72.
What's in the News
- Launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling test for noninvasive therapy selection and monitoring, expanding presence in the $3-5 billion liquid biopsy market.
- Lowered 2025 guidance, expecting revenue of $720–$726 million (prior $747–$759 million) and a net loss of $116–$108 million (prior $85–$77 million).
- Introduced PanTracer Tissue and PanTracer Tissue + HRD, next-generation solid tumor profiling assays, enabling faster results and enhanced tumor profiling, revealed at ASCO.
- Unveiled PanTracer Family portfolio and Paletrra, an AI-driven spatial proteomics platform, at ASCO, reinforcing NeoGenomics’ role in precision oncology and translational research.
- Commercially launched c-MET CDx for NSCLC, a rapid companion diagnostic assay supporting timely treatment selection for MET-targeted therapies.
Valuation Changes
Summary of Valuation Changes for NeoGenomics
- The Consensus Analyst Price Target has significantly fallen from $11.05 to $8.72.
- The Future P/E for NeoGenomics has significantly fallen from 40.88x to 31.52x.
- The Consensus Revenue Growth forecasts for NeoGenomics has significantly fallen from 11.5% per annum to 9.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.